Bayer Launches Centafore to Boost Digital Imaging & SaMD Services for Clinical Trials

It aims to improve the reliability of trial outcomes through advanced image analysis, and a network of experienced imaging professionals, including board-certified radiologists, operating across more than 50 countries.

Bayer has announced the launch of Centafore, a dedicated imaging core lab service designed to support clinical trials and Software as a Medical Device (SaMD) development across multiple therapeutic areas and trial phases.

With over 25 years of internal experience managing imaging for more than 200 clinical trials, Centafore will now extend its services to external pharmaceutical, biotech, medical device, and digital health companies.

Positioned as an imaging contract research organization (iCRO), Centafore offers technology and services for image management, processing, and interpretation.

Moreover, it aims to improve the reliability of trial outcomes through expert project management, advanced image analysis, and a network of experienced imaging professionals, including board-certified radiologists, operating across more than 50 countries.

“Centafore represents a significant leap forward in our commitment to enhancing the landscape of clinical trial imaging and advancing the development of new medicines and healthcare solutions,” said Nelson Ambrogio, president of radiology at Bayer.

“By leveraging our extensive experience and expertise, we are dedicated to providing our customers with high quality imaging services that meet their specific needs in clinical research. Through Centafore, we aim to enhance the reliability of trial outcomes and support informed decision-making in the development of investigational medicines, ultimately benefiting patients and improving their quality of care.”

Centafore’s services cover a range of therapeutic areas, including oncology, cardiovascular, CNS, dermatology, women’s health, pediatrics, and digital health. In addition to supporting clinical research from early-stage studies through phase IV trials, it also provides compliance-driven imaging solutions for SaMD development.

The launch of Centafore follows Bayer’s broader initiatives to strengthen its digital health and radiology capabilities. Centafore was first introduced at ECR 2024 and has since collaborated with organizations such as OBIO and Luxsonic Technologies to integrate imaging as a critical decision-making tool in clinical trials and software-based medical solutions.

Last year, Bayer announced plans to acquire HiDoc Technologies GmbH in the first quarter of 2025. The acquisition included the commercialization of the digital health application Cara Care, which is the first prescribed app for the treatment of irritable bowel syndrome (IBS).

Cara Care offers a holistic, personalized approach to managing IBS, helping patients understand their condition better and control symptoms more effectively.

Stay tuned for more such updates on Digital Health News.

Stay tuned for more such updates on Digital Health News